Condition 1: Refractory acute myeloid leukemia. Condition 2: relapsed acute myeloid leukemia. Acute myeloblastic leukemia, not having achieved remission Acute myeloblastic leukemia, in relapse
Conditions
Interventions
Intervention 1: Intervention group: Patients with refractory or relapsed acute myeloid leukemia who receive Fludarabine 30mg/m2/day D1 to D5 IV - Cytarabine 2gr/m2/day D1 to D5 IV-Noantrone(mitoxantro
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1- Patients with refractory or relapsed acute myeloid leukemia in the age range of 15-60 years 2- Performance status based on Karnofsky criteria above 70 or ECOG = 1-2 EF (cardiac output) greater than 45 percent obtaining informed consent
Exclusion criteria
Exclusion criteria: 1- Occurrence of grade 3 or 4 drug toxicity 2- Heart, Respiratory, or Renal failure 3- Performance status based on Karnofsky criteria below 70 or ECOG =3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achieving bone marrow remission. Timepoint: Two weeks after starting treatment. Method of measurement: Bone marrow aspiration and biopsy and pathologist report.;Drug Toxicity. Timepoint: one month. Method of measurement: Daily clinical examinations and use of checklist.;Cause of death. Timepoint: During hospitalization. Method of measurement: Reviewing patient's file documents. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmadreza Maghsoudi
Esfahan University of Medical Sciences
Outcome results
None listed